Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
22
PRPH Quote, Financials, Valuation and Earnings
Last price:
$0.59
Seasonality move
:
13.04%
Day range:
$0.80 - $1.15
52-week range:
$0.64 - $9.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.47x
P/B ratio:
0.46x
Volume:
2.8M
Avg. volume:
1.7M
1-year change:
-84.11%
Market cap:
$3.2M
Revenue:
$6.8M
EPS (TTM):
-$7.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$285K | -$0.24 | -80.82% | -75.61% | $7.00 |
|
VCYT
Veracyte, Inc.
|
$124.9M | $0.32 | 11.04% | 511.28% | $47.50 |
|
XGN
Exagen, Inc.
|
$16.9M | -$0.16 | 26.43% | -14.75% | $15.43 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRPH
ProPhase Labs, Inc.
|
$0.69 | $13.80 | $3.2M | -- | $0.00 | 0% | 0.47x |
|
FONR
FONAR Corp.
|
$14.52 | -- | $91.4M | 13.13x | $0.00 | 0% | 0.88x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$5.41 | $7.00 | $155.1M | -- | $0.00 | 0% | 32.92x |
|
VCYT
Veracyte, Inc.
|
$42.92 | $47.50 | $3.4B | 113.07x | $0.00 | 0% | 6.89x |
|
XGN
Exagen, Inc.
|
$6.32 | $15.43 | $143.2M | -- | $0.00 | 0% | 2.01x |
|
XWEL
XWELL, Inc.
|
$0.62 | -- | $3.6M | -- | $0.00 | 0% | 0.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRPH
ProPhase Labs, Inc.
|
52.83% | -0.268 | 40.4% | 0.07x |
|
FONR
FONAR Corp.
|
18.59% | 1.654 | 49.09% | 9.64x |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-51.52% | -0.107 | 3.29% | 2.57x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.341 | 1.49% | 5.74x |
|
XGN
Exagen, Inc.
|
60.83% | 0.117 | 11.39% | 3.63x |
|
XWEL
XWELL, Inc.
|
278.04% | 1.263 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-$423K | -$7.7M | -1767.73% | -1008.03% | -2950% | -$5.6M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XGN
Exagen, Inc.
|
$10.1M | -$3.1M | -49.66% | -140.03% | -17.98% | $2.7M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
ProPhase Labs, Inc. vs. Competitors
-
Which has Higher Returns PRPH or FONR?
FONAR Corp. has a net margin of -774.52% compared to ProPhase Labs, Inc.'s net margin of 10.25%. ProPhase Labs, Inc.'s return on equity of -90.24% beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About PRPH or FONR?
ProPhase Labs, Inc. has a consensus price target of $13.80, signalling upside risk potential of 19987.34%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that ProPhase Labs, Inc. has higher upside potential than FONAR Corp., analysts believe ProPhase Labs, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs, Inc.0 0 0 FONRFONAR Corp.0 0 0 -
Is PRPH or FONR More Risky?
ProPhase Labs, Inc. has a beta of -0.657, which suggesting that the stock is 165.684% less volatile than S&P 500. In comparison FONAR Corp. has a beta of 1.000, suggesting its less volatile than the S&P 500 by 0.021000000000004%.
-
Which is a Better Dividend Stock PRPH or FONR?
ProPhase Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs, Inc. pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or FONR?
ProPhase Labs, Inc. quarterly revenues are $883K, which are smaller than FONAR Corp. quarterly revenues of $26M. ProPhase Labs, Inc.'s net income of -$6.8M is lower than FONAR Corp.'s net income of $2.7M. Notably, ProPhase Labs, Inc.'s price-to-earnings ratio is -- while FONAR Corp.'s PE ratio is 13.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs, Inc. is 0.47x versus 0.88x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs, Inc.0.47x -- $883K -$6.8M FONRFONAR Corp.0.88x 13.13x $26M $2.7M
-
Which has Higher Returns PRPH or IMDX?
Insight Molecular Diagnostics, Inc. has a net margin of -774.52% compared to ProPhase Labs, Inc.'s net margin of -4174.62%. ProPhase Labs, Inc.'s return on equity of -90.24% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M -
What do Analysts Say About PRPH or IMDX?
ProPhase Labs, Inc. has a consensus price target of $13.80, signalling upside risk potential of 19987.34%. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 29.39%. Given that ProPhase Labs, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs, Inc.0 0 0 IMDXInsight Molecular Diagnostics, Inc.1 2 0 -
Is PRPH or IMDX More Risky?
ProPhase Labs, Inc. has a beta of -0.657, which suggesting that the stock is 165.684% less volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.183, suggesting its more volatile than the S&P 500 by 18.332%.
-
Which is a Better Dividend Stock PRPH or IMDX?
ProPhase Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs, Inc. pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or IMDX?
ProPhase Labs, Inc. quarterly revenues are $883K, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. ProPhase Labs, Inc.'s net income of -$6.8M is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, ProPhase Labs, Inc.'s price-to-earnings ratio is -- while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs, Inc. is 0.47x versus 32.92x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs, Inc.0.47x -- $883K -$6.8M IMDXInsight Molecular Diagnostics, Inc.32.92x -- $260K -$10.9M
-
Which has Higher Returns PRPH or VCYT?
Veracyte, Inc. has a net margin of -774.52% compared to ProPhase Labs, Inc.'s net margin of 14.51%. ProPhase Labs, Inc.'s return on equity of -90.24% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About PRPH or VCYT?
ProPhase Labs, Inc. has a consensus price target of $13.80, signalling upside risk potential of 19987.34%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 10.67%. Given that ProPhase Labs, Inc. has higher upside potential than Veracyte, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Veracyte, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs, Inc.0 0 0 VCYTVeracyte, Inc.8 2 1 -
Is PRPH or VCYT More Risky?
ProPhase Labs, Inc. has a beta of -0.657, which suggesting that the stock is 165.684% less volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.
-
Which is a Better Dividend Stock PRPH or VCYT?
ProPhase Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or VCYT?
ProPhase Labs, Inc. quarterly revenues are $883K, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. ProPhase Labs, Inc.'s net income of -$6.8M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, ProPhase Labs, Inc.'s price-to-earnings ratio is -- while Veracyte, Inc.'s PE ratio is 113.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs, Inc. is 0.47x versus 6.89x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs, Inc.0.47x -- $883K -$6.8M VCYTVeracyte, Inc.6.89x 113.07x $131.9M $19.1M
-
Which has Higher Returns PRPH or XGN?
Exagen, Inc. has a net margin of -774.52% compared to ProPhase Labs, Inc.'s net margin of -41.1%. ProPhase Labs, Inc.'s return on equity of -90.24% beat Exagen, Inc.'s return on equity of -140.03%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M XGNExagen, Inc.58.43% -$0.31 $46.3M -
What do Analysts Say About PRPH or XGN?
ProPhase Labs, Inc. has a consensus price target of $13.80, signalling upside risk potential of 19987.34%. On the other hand Exagen, Inc. has an analysts' consensus of $15.43 which suggests that it could grow by 144.12%. Given that ProPhase Labs, Inc. has higher upside potential than Exagen, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Exagen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs, Inc.0 0 0 XGNExagen, Inc.8 0 0 -
Is PRPH or XGN More Risky?
ProPhase Labs, Inc. has a beta of -0.657, which suggesting that the stock is 165.684% less volatile than S&P 500. In comparison Exagen, Inc. has a beta of 1.801, suggesting its more volatile than the S&P 500 by 80.089%.
-
Which is a Better Dividend Stock PRPH or XGN?
ProPhase Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exagen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs, Inc. pays -- of its earnings as a dividend. Exagen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or XGN?
ProPhase Labs, Inc. quarterly revenues are $883K, which are smaller than Exagen, Inc. quarterly revenues of $17.2M. ProPhase Labs, Inc.'s net income of -$6.8M is higher than Exagen, Inc.'s net income of -$7.1M. Notably, ProPhase Labs, Inc.'s price-to-earnings ratio is -- while Exagen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs, Inc. is 0.47x versus 2.01x for Exagen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs, Inc.0.47x -- $883K -$6.8M XGNExagen, Inc.2.01x -- $17.2M -$7.1M
-
Which has Higher Returns PRPH or XWEL?
XWELL, Inc. has a net margin of -774.52% compared to ProPhase Labs, Inc.'s net margin of -2.87%. ProPhase Labs, Inc.'s return on equity of -90.24% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About PRPH or XWEL?
ProPhase Labs, Inc. has a consensus price target of $13.80, signalling upside risk potential of 19987.34%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1025.04%. Given that ProPhase Labs, Inc. has higher upside potential than XWELL, Inc., analysts believe ProPhase Labs, Inc. is more attractive than XWELL, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRPHProPhase Labs, Inc.0 0 0 XWELXWELL, Inc.0 0 0 -
Is PRPH or XWEL More Risky?
ProPhase Labs, Inc. has a beta of -0.657, which suggesting that the stock is 165.684% less volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.697%.
-
Which is a Better Dividend Stock PRPH or XWEL?
ProPhase Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRPH or XWEL?
ProPhase Labs, Inc. quarterly revenues are $883K, which are smaller than XWELL, Inc. quarterly revenues of $7.3M. ProPhase Labs, Inc.'s net income of -$6.8M is lower than XWELL, Inc.'s net income of -$211K. Notably, ProPhase Labs, Inc.'s price-to-earnings ratio is -- while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs, Inc. is 0.47x versus 0.11x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRPHProPhase Labs, Inc.0.47x -- $883K -$6.8M XWELXWELL, Inc.0.11x -- $7.3M -$211K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
